308 related articles for article (PubMed ID: 17062316)
1. Dosing patterns and costs of erythropoietic agents in patients with chronic kidney disease not on dialysis in managed care organizations.
Duh MS; Mody SH; Scott McKenzie R; Lefebvre P; Gosselin A; Tak Piech C
Clin Ther; 2006 Sep; 28(9):1443-50. PubMed ID: 17062316
[TBL] [Abstract][Full Text] [Related]
2. Dosing patterns and treatment costs of erythropoietic agents in elderly patients with pre-dialysis chronic kidney disease in managed care organisations.
Duh MS; Mody SH; McKenzie RS; Lefebvre P; Gosselin A; Bookhart BK; Piech CT
Drugs Aging; 2006; 23(12):969-76. PubMed ID: 17154661
[TBL] [Abstract][Full Text] [Related]
3. Dosing patterns, treatment costs, and frequency of physician visits in adults with cancer receiving erythropoietic agents in managed care organizations.
Lefebvre P; Gosselin A; McKenzie RS; Mody SH; Piech CT; Duh MS
Curr Med Res Opin; 2006 Sep; 22(9):1623-31. PubMed ID: 16968565
[TBL] [Abstract][Full Text] [Related]
4. Dosing patterns, hematologic outcomes, and costs of erythropoietic agents in anemic predialysis chronic kidney disease patients from an observational study.
Papatheofanis F; Smith C; Mody S; McKenzie RS; Bookhart B; Piech CT
Am J Ther; 2007; 14(4):322-7. PubMed ID: 17667204
[TBL] [Abstract][Full Text] [Related]
5. Dosing patterns, hematologic outcomes, and costs of erythropoietic agents in predialysis chronic kidney disease patients with anemia.
Papatheofanis FJ; McKenzie RS; Mody SH; Suruki RY; Piech CT
Curr Med Res Opin; 2006 May; 22(5):837-42. PubMed ID: 16709305
[TBL] [Abstract][Full Text] [Related]
6. Drug utilisation and cost considerations of erythropoiesis stimulating agents in oncology patients receiving chemotherapy: observations from a large managed-care database.
Vekeman F; McKenzie RS; Bookhart BK; Laliberté F; Duh MS; Tak Piech C; Lefebvre P
J Med Econ; 2009 Mar; 12(1):1-8. PubMed ID: 19450059
[TBL] [Abstract][Full Text] [Related]
7. Dosing intervals and hemoglobin control in patients with chronic kidney disease and anemia treated with epoetin alfa or darbepoetin alfa: a retrospective cohort study.
Nurko S; Spirko R; Law A; Dennis VW
Clin Ther; 2007 Sep; 29(9):2010-21. PubMed ID: 18035200
[TBL] [Abstract][Full Text] [Related]
8. Dosing patterns, drug costs, and hematologic outcome in anemic patients with chronic kidney disease switching from darbepoetin alfa to epoetin alfa.
Hymes J; Bickimer T; Jackson JH; Bookhart BK; Mody SH; Tak Piech C
Curr Med Res Opin; 2007 Aug; 23(8):1931-7. PubMed ID: 17624232
[TBL] [Abstract][Full Text] [Related]
9. Cost analysis of erythropoietic-stimulating therapy dosing in oncology inpatients.
Killian AD; Gupta V; Goetz AE
Ann Pharmacother; 2006 Mar; 40(3):421-6. PubMed ID: 16507613
[TBL] [Abstract][Full Text] [Related]
10. Utilization and cost comparison of erythropoiesis-stimulating agents in inpatient and outpatient hospital settings.
Lafeuille MH; Bailey RA; Vekeman F; Scott McKenzie R; Lefebvre P
J Med Econ; 2012; 15(2):352-60. PubMed ID: 22168787
[TBL] [Abstract][Full Text] [Related]
11. Propensity score matched assessment of treatment patterns and cost of erythropoiesis stimulating agent treatment in patients with cancer receiving myelosuppressive chemotherapy.
Tunceli O; Bailey RA; Stephenson JJ; Singer J
J Oncol Pharm Pract; 2013 Dec; 19(4):305-14. PubMed ID: 23235918
[TBL] [Abstract][Full Text] [Related]
12. The cost-effectiveness of weekly epoetin alfa relative to weekly darbepoetin alfa in patients with chemotherapy-induced anemia.
Ben-Hamadi R; Duh MS; Aggarwal J; Henckler A; McKenzie RS; Tak Piech C
Curr Med Res Opin; 2005 Oct; 21(10):1677-82. PubMed ID: 16238908
[TBL] [Abstract][Full Text] [Related]
13. Cost analytic model to determine the least costly inpatient erythropoiesis stimulating therapy regimen.
Sikand H; Decter A; Greco T; Watson SH; Kang YJ; Mody SH; Piech CT; Duh MS; Naeem A
Ann Pharmacother; 2008 Jan; 42(1):16-23. PubMed ID: 18029428
[TBL] [Abstract][Full Text] [Related]
14. Drug utilization and cost for erythropoiesis-stimulating agents in a long-term care resident population with chronic kidney disease.
Lafeuille MH; Bailey RA; Vekeman F; Kilpatrick BS; Senbetta M; Piech CT; Lefebvre P
Consult Pharm; 2010 Aug; 25(8):493-500. PubMed ID: 20736158
[TBL] [Abstract][Full Text] [Related]
15. Retrospective observational study of patients with chemotherapy-related anemia receiving erythropoietic agents.
Mark TL; McKenzie RS; Fastenau J; Piech CT
Curr Med Res Opin; 2005 Sep; 21(9):1347-54. PubMed ID: 16197652
[TBL] [Abstract][Full Text] [Related]
16. Health economic evaluation of treating anemia in cancer patients receiving chemotherapy: a study in Belgian hospitals.
Spaepen E; Demarteau N; Van Belle S; Annemans L
Oncologist; 2008 May; 13(5):596-607. PubMed ID: 18515745
[TBL] [Abstract][Full Text] [Related]
17. Outcomes of erythropoiesis-stimulating agents in cancer patients with chemotherapy-induced anemia.
Pashos CL; Larholt K; Fraser KA; McKenzie RS; Senbetta M; Piech CT
Support Care Cancer; 2012 Jan; 20(1):159-65. PubMed ID: 21359879
[TBL] [Abstract][Full Text] [Related]
18. Use and cost of erythropoiesis-stimulating agents in patients with cancer.
Daniel G; Hurley D; Whyte JL; Willey V; Wilson M; Kallich J
Curr Med Res Opin; 2009 Jul; 25(7):1775-84. PubMed ID: 19505205
[TBL] [Abstract][Full Text] [Related]
19. Drug administration frequency and provider office visit patterns for oncology patients during treatment with erythropoietic agents: an analysis of four observational studies.
Gosselin A; Pashos CL; Harley C; Mark TL; McKenzie RS
Clin Ther; 2006 Oct; 28(10):1701-8. PubMed ID: 17157126
[TBL] [Abstract][Full Text] [Related]
20. Estimate of maintenance EPO to darbepoetin alfa dose conversion ratio in a hospital-based dialysis patient population.
Sharma A; Yee J; Gandra SR; Khan I; Petersen J
Curr Med Res Opin; 2010 Nov; 26(11):2679-87. PubMed ID: 20942616
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]